JMP reiterates Critical Therapeutics at buy

Critical Therapeutics, Inc. was reiterated by JMP Securities analyst Adam Cutler after the company's overall second-quarter financial results met estimates. Total revenues of $3.5 million beat JMP's estimate of $3.1 million and the Street consensus estimate of $3.3 million. Critical Therapeutics' shares as undervalued, according to the analyst. Upcoming data could possibly be positive catalysts for the stock but the company's need for capital could create near-term overhang. Shares of the Lexington, Mass.-based biopharmaceutical company were down 10 cents, or 2.42%, at $4.04, on volume of 92,381 shares versus the three-month running average of 61,138 shares. (Nasdaq: CRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.